PHOTO
Olfat Berro will be responsible for driving the company's ambitious growth plans in key therapeutic areas in Lebanon
Beirut - Roche announced the appointment of Olfat Berro as the new Country Manager for its pharmaceutical business in Lebanon. Following a long proficient experience at Roche since 2003, Olfat will now report to Olaf Schulzeck, General Manager of Middle East Sub-region II, to become a member of the Middle East II Leadership Team. Her new position, effective from July 2015, emphasizes Roche's efforts to initiate growth in the healthcare industry in Lebanon.
Commenting on her new responsibility, Olfat Berro stated, "Roche has always been a great place to work and I look forward to lead the high achieving and motivated team in Lebanon to reach our goals within the changing environment. I will be working closely with local healthcare providers and institutions to increase the level of disease awareness within our community while ensuring that all patients benefit from our innovative medicines and help more people have access to treatment."
Continuing her lengthy career path at Roche, Olfat Berro has been involved in diverse fields and has been committed to the company since 2003, handling advanced local and regional roles starting as a Product Specialist and Product Manager. In addition, Olfat managed to hold the role of the Business Unit Manager for the RA, Virology and Transplantation Unit in Lebanon since 2010 and most recently the position of theBusiness Unit Manager of Oncology.
Roche commenced its licensed operations in 1997, and has grown to become a Middle East sub-region for 16 markets including the UAE, Saudi Arabia, Egypt, Iraq, Iran, Qatar, Kuwait, Bahrain, Oman, Yemen, Syria, Jordan, Palestine, Lebanon, Pakistan and Afghanistan, with almost 500 employees across the region.
-Ends-
About Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the World Health Organisation Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.
In 2013 the Roche Group employed over 85,000 people worldwide, invested 8.7 billion Swiss francs in R&D and posted sales of 46.8 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
Further information:
Roche Lebanon SARL
Maya Helbaoui
Communications Manager
Phone +961-76-885591
Fax +961 1 989 113
E-mail: maya.helbaoui@roche.com
www.roche.com
Memac Ogilvy PR
Blanche Baz
Layale Abou Antoun
Phone +961 1 486 066
Fax +961 1 486 064
Email layale.abouantoun@ogilvy.com
© Press Release 2015
